Other
Smoking
3
Pipeline Programs↗
13
Active Trials↗
8
Companies Involved↗
Smoking is an early-stage landscape with 3 programs across 8 companies. The most active players are Glaxo Dba Glaxosmithkline, Pfizer, Teva. 3 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Analysis
Trial Status
86
clinical trials
Completed70 · 81%
Recruiting8 · 9%
Terminated3 · 3%
Enrolling by invitation3 · 3%
Not yet recruiting2 · 2%
Clinical Trials
Trial Activity
86 trials
Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking
Recruiting·—·Phase 1·NCT05665465·150 enrolled
Use of Noninvasive Wearables Biomonitoring to Detect Pre-Smoking, Smoking, And Post-Smoking Stages: An Observational Laboratory Study
Enrolling by invitation·National Institute on Minority Health and Health Disparities (NIMHD)·N/A·NCT07067151·30 enrolled
Effect of Donepezil on Smoking
Completed·—·Phase 2·NCT01250977·30 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)